How to Prevent And/or Revert Alzheimer's Disease Continuum During Preclinical Phases

Overview

Journal J Alzheimers Dis Rep

Publisher IOS Press

Date 2023 Jun 14

PMID 37313496

Authors

Marina Avila-Villanueva

Alberto Marcos Dolado

Miguel Fernandez-Blazquez

Affiliations

Soon will be listed here.

Abstract

The development of Alzheimer's disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of "precision medicine" in healthcare systems worldwide.

References

Avila-Villanueva M, Gomez-Ramirez J, Avila J, Fernandez-Blazquez M . Loneliness as Risk Factor for Alzheimer´s disease. Curr Aging Sci. 2022; 15(3):293-296. DOI: 10.2174/1874609815666220304195049. View

Sanz-Blasco R, Ruiz-Sanchez de Leon J, Avila-Villanueva M, Valenti-Soler M, Gomez-Ramirez J, Fernandez-Blazquez M . Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models. Alzheimers Dement. 2021; 18(6):1177-1185. DOI: 10.1002/alz.12448. View

Adlard P, Perreau V, Pop V, Cotman C . Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005; 25(17):4217-21. PMC: 6725122. DOI: 10.1523/JNEUROSCI.0496-05.2005. View

Jack Jr C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. PMC: 3622225. DOI: 10.1016/S1474-4422(12)70291-0. View

Nassan M, Videnovic A . Circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2021; 18(1):7-24. DOI: 10.1038/s41582-021-00577-7. View

Omura J, McGuire L, Patel R, Baumgart M, Lamb R, Jeffers E . Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged ≥45 Years - United States, 2019. MMWR Morb Mortal Wkly Rep. 2022; 71(20):680-685. PMC: 9129905. DOI: 10.15585/mmwr.mm7120a2. View

van Lent D, Egert S, Wolfsgruber S, Kleineidam L, Weinhold L, Wagner-Thelen H . Low Serum Vitamin D Status Is Associated with Incident Alzheimer's Dementia in the Oldest Old. Nutrients. 2023; 15(1). PMC: 9824107. DOI: 10.3390/nu15010061. View

Edwards Iii G, Gamez N, Escobedo Jr G, Calderon O, Moreno-Gonzalez I . Modifiable Risk Factors for Alzheimer's Disease. Front Aging Neurosci. 2019; 11:146. PMC: 6601685. DOI: 10.3389/fnagi.2019.00146. View

Flicker L . Modifiable lifestyle risk factors for Alzheimer's disease. J Alzheimers Dis. 2010; 20(3):803-11. DOI: 10.3233/JAD-2010-091624. View

10.

Olsson M, Arlig J, Hedner J, Blennow K, Zetterberg H . Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. Sleep. 2018; 41(5). DOI: 10.1093/sleep/zsy025. View

11.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley R . Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016; 139(Pt 4):1252-64. DOI: 10.1093/brain/aww017. View

12.

Petersen R . Clinical practice. Mild cognitive impairment. N Engl J Med. 2011; 364(23):2227-34. DOI: 10.1056/NEJMcp0910237. View

13.

Stern Y . Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012; 11(11):1006-12. PMC: 3507991. DOI: 10.1016/S1474-4422(12)70191-6. View

14.

McGuinness B, Todd S, Passmore P, Bullock R . Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009; (4):CD004034. PMC: 7163274. DOI: 10.1002/14651858.CD004034.pub3. View

15.

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

16.

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

17.

Ozcan G, Lim S, Leighton P, Allison W, Rihel J . Sleep is bi-directionally modified by amyloid beta oligomers. Elife. 2020; 9. PMC: 7360368. DOI: 10.7554/eLife.53995. View

18.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

19.

Jensen-Dahm C, Werner M, Dahl J, Jensen T, Ballegaard M, Hejl A . Quantitative sensory testing and pain tolerance in patients with mild to moderate Alzheimer disease compared to healthy control subjects. Pain. 2014; 155(8):1439-1445. DOI: 10.1016/j.pain.2013.12.031. View

20.

Avila-Villanueva M, Gomez-Ramirez J, Maestu F, Venero C, Avila J, Fernandez-Blazquez M . The Role of Chronic Stress as a Trigger for the Alzheimer Disease Continuum. Front Aging Neurosci. 2020; 12:561504. PMC: 7642953. DOI: 10.3389/fnagi.2020.561504. View